Figure 2From: Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials Mean changes in Disease Activity Score 28 (DAS28) in Parts A, B and C. Back to article page